期刊
SCIENCE
卷 365, 期 6457, 页码 1033-+出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aaw7765
关键词
-
资金
- Intramural Research Program of the Vaccine Research Center, National Institutes of Health
- Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health
- National Cancer Institute, National Institutes of Health [HSN261200800001E]
- NHP Reagent Resource grants [OD010976, AI126683T]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI005126, ZIAAI005021, ZIAAI005022, ZICAI005103] Funding Source: NIH RePORTER
A study in nonhuman primates reported that infusions of an antibody against alpha(4)beta(7) integrin, in combination with antiretroviral therapy, showed consistent, durable control of simian immunodeficiency virus (SIV) in rhesus macaques. The antibody used has pleiotropic effects, so we set out to gain insight into the underlying mechanism by comparing this treatment to treatment with non-neutralizing monoclonal antibodies against the SIV envelope glycoprotein that only block alpha(4)beta(7) binding to SIV Env but have no other host-directed effects. Similar to the initial study, we used an attenuated strain of SIV containing a stop codon in nef. The study used 30 macaques that all began antiretroviral therapy and then were divided into five groups to receive different antibody treatments. Unlike the published report, we found no sustained virologic control by these treatments in vivo.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据